Oncoprobe, a cancer theranostics company, has announced the completion of a significant equity-financing round with a syndicate of private investors including those from the previous funding round
"This new additional investment reflects the confidence felt by investors in our company and its platform technology.
"The funding will allow us to meet our plan to roll out a theranostics strategy internationally in partnership with major cancer treatment centres here and in the USA" commented Jim Bristow, the company's chairman.
"We have been delighted with the progress the technical team, in partnership with Uniscan Instruments and DuPont UK , have made with the development of our prototype instrument, and this investment finance will enable us to conduct clinical evaluations in conjunction with our clinical collaborators at the Christie Hospital in Manchester" he said.
Oncoprobe will work closely with clinical oncologists at the Christie Hospital to evaluate the utility of its theranostics instrument in selecting optimal treatment regimes for renal cancer patients initially, moving on to assess its suitability for ovarian and colorectal cancer in the future.
Noel Clarke, head of the genito-urinary cancer research group at the Christie Hospital said, "We are delighted that Oncoprobe has completed this investment round.
"We now look forward to working closely with the University Department of Medicine to conduct the clinical assessment of its theranostics technology, which offers great promise in the selection of the most effective therapies for individual cancer patients."
